Why Genenta Science S.p.A.’s (GNTA) Stock Is Down 5.45%
As of Wednesday, June 03, Genenta Science S.p.A.’s GNTA share price has dipped by 5.45%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring majority or full ownership of privately held, established companies operating in Italian national-security-regulated sectors. Its activities and acquisition strategy span aerospace, defense, national security (including cybersecurity), and biotechnology/biosecurity. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Commentary & Analysis
Why Genenta Science S.p.A.’s (GNTA) Stock Is Down 43.23%
As of Monday, October 27, Genenta Science S.p.A.’s GNTA share price has dipped by 43.23%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Genenta Science S.p.A.’s (GNTA) Stock Is Up 98.79%
As of Friday, October 24, Genenta Science S.p.A.’s GNTA share price has surged by 98.79%, which has investors questioning if this is right time to sell.Tudor Pop
Why Genenta Science S.p.A.’s (GNTA) Stock Is Up 7.59%
As of Wednesday, October 15, Genenta Science S.p.A.’s GNTA share price has surged by 7.59%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Genenta Science S.p.A.’s (GNTA) Stock Is Down 10.66%
As of Tuesday, October 14, Genenta Science S.p.A.’s GNTA share price has dipped by 10.66%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | GNTA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $19.6 | $270.6 | 10% |
|
| Shares Out (Mil) | 24.2 | 54.4 | 34% |
|
| Institutional Ownership | 17.0% | 92.9% | 9% |
|
| Float (Mil) | 13.9 | 41.4 | 23% |
|
| Beta | 0.90 | 0.94 | 54% |
|
| Avg Daily Volume (000s) | 50 | 481 | 28% |
|
| Price Change (52-week) |
(69.8%) | 55.6% | 10% |
|
| Growth | GNTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (2.5%) | (10.1%) | 37% |
|
| EPS (5yr) | 3.7% | 15.8% | 36 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 16.6% | (15.6%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | GNTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($8) | ($43) | 31% |
|
| EPS (TTM) | ($0.389) | ($1.500) | 29% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $2 | 46% |
|
| Long-Term Debt (Q1) (Mil) | $9 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | $25 | $179 | 12% |
|
| Valuation | GNTA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.76 | 2.63 | 14% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | GNTA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.2% | na |
|
| Net Margin | na | (73.0%) | na |
|
| ROA | (29.0%) | (47.9%) | 17% |
|
| ROE | (39.7%) | (55.0%) | 17% |
|
| Liabilities to Assets | 31.5% | 29.4% | 23% |
|
| F-Score | 2 | 3 | 7% |
|
Genenta Science S.p.A. did not pass any screens on 9/14/2026.
